Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUKDEN 01 Plus: Pyrotinib, Dalpiciclib, Trastuzumab, and Letrozole in TPBC
NCT05228951Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib, dalpiciclib in breast cancer, sponsored by Shengjing Hospital of China Medical University. Started Feb 2022; status: recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05228951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228951.